A follow-up to my post from a few weeks ago on Bellicum Pharmaceutical’s clinical trial hold, and the market’s (over)reaction. Yesterday, Bellicum issued an anodyne press release regarding discussions with the FDA on lifting the clinical hold on U.S. studies of BPX-501:
To address the FDA requirements, the Company plans to implement revisions to the U.S. study protocols, including the addition of more comprehensive monitoring and management of neurotoxicity. In addition, the Company will revise the Investigator Brochure and Informed Consent Documents to inform healthcare providers, patients and caregivers of the changes.
Good news. Bellicum’s stock continued its recovery of the past month, $7.03 as of the Feb. 23 close, up from Jan. 31 opening price of $5.21. That’s a gain of 35% in less than a month, a very nice recovery indeed. The stock does remain 14% below the Jan 30. close of $8.20, however, a reminder of the investing truism that a 37% loss takes more than a 37% gain to recover initial value.
Originally posted (on LinkedIn) 2018-02-24
I grew up in Northern California. After studying chemistry at M.I.T. for 8 years (S.B.; Ph.D, with Fred Greene), I moved up the river to Harvard to learn structural biology with Steve Harrison.